González MJ, Miranda-Massari JR, Mora EM, Jiménez IZ, Matos MI, Riordan HD, Casciari JJ, Riordan
NH, Rodríguez M, Guzmán A.
University of Puerto Rico, Medical Sciences Campus, School of Public Health, Dept. Human Development, Nutrition
Program, RECNAC II Project, GPO Box 365067, San Juan, PR, USA.
The effect of vitamin C in cancer has been a subject of great controversy; mainly because of the inconsistent results obtained by oral intakes of ascorbate when used as an anticancer agent. We believe the intravenous application of ascorbate will provide more consistent results in cancer patients since Vitamin C blood levels attained are substantially higher in a range proven cytotoxic to malignant cells. In this article we will present and discuss our proposed mechanism on the chemotherapeutic activity exhibited by ascorbate.
PMID: 12013679 [PubMed – indexed for MEDLINE] P R Health Sci J. 2004 Jun;23(2):1158.
Riordan HD, Riordan NH, Jackson JA, Casciari JJ, Hunninghake R, González MJ, Mora EM, MirandaMassari
JR, Rosario N, Rivera A.
Center for the Improvement of Human Functioning, RENAC Project, Wichita, KS, USA.
A series of seven cases are presented in which intravenous vitamin C has been used as antineoplastic agent in the treatment of different types of cancers. The cancers cases reviewed are the following: Renal cell carcinoma (2), Colorectal cancer (1), Pancreatic cancer (1), Non-Hodgkin’s lymphoma (2) and breast cancer (1). Toxic reactions were not observed at these high doses of intravenous Vitamin C. All patients were prescreened for Glucose 6–phosphate dehydrogenase deficiency before administering intravenous Vitamin C
in order to prevent hemolysis.
PMID: 15377059 [PubMed – indexed for MEDLINE]